medroxyprogesterone acetate has been researched along with Hematologic Diseases in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bunce, CM; Craddock, CF; Drayson, MT; Hayden, RE; Holyoake, TL; Jackson, N; Khanim, FL; Lumley, M; Murray, JA | 1 |
1 trial(s) available for medroxyprogesterone acetate and Hematologic Diseases
| Article | Year |
|---|---|
Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bezafibrate; Female; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male; Medroxyprogesterone Acetate; Middle Aged; Recurrence; Treatment Outcome | 2010 |